

InnovaDerma PLC

09:01 02 Jul 2019

InnovaDerma shines as it forecasts doubling of full year profits

InnovaDerma PLC (LON:IDP) shares were brighter on Tuesday after predicting that its pre-tax profits would more than double after strong trading in its last financial year.

In a trading update for the 12 months ended 30 June, the maker of beauty and personal care products said revenues had increased by 21% to £13m, and, as a result, pre-tax profits were expected to have more than doubled from the £670,000 reported in 2018, in line with expectations.

READ: InnovaDerma reports strong start to second-half after navigating Facebook advertising changes

Gross margins had also "improved significantly", the firm said, rising around 500 basis points year-on-year as a result of what it said was the agility of its business model which enabled it to scale its brands without increasing its overhead costs.

InnovaDerma said all its brands, including its popular Skinny Tan spray tanning product, had performed well during the year delivering both revenue and profit growth.

Skinny Tan, in particular, had contributed strongly as new product launches and a "significant increase" in the retail footprint of the brand, which is sold in 2,300 stores including Boots, Superdrug and Asda, helped drive sales.

The strong retail performance had also boosted the company's cash generation over the year, meaning its cash balance for the period had come in at £1.7m, which executive chairman Haris Chaudhry said was "ahead of guidance".

Chaudhry added that going forward the group would be focusing on product innovation and launching new brands into new territories and categories, the combination of which would "further accelerate growth" in the new financial year.

The company's full results for the period are expected in September.

In a note, analysts at InnovaDerma's 'house' broker finnCap maintained their target price for the firm at 200p, saying the update provided a "strong platform" to develop the business further.


The broker added that the update should provide investors with "comfort" following a lack of newsflow since the company's interims in February.

In early deals, the shares were 3.3% higher at 110.5p.

Price: 78

Market Cap: £11.31 m

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: IDP

Listing: LSE

52 week High Low
116.88 47.5

Sector: Fashion & brands

Website: www.innovaderma.com

Company Synopsis:

InnovaDerma PLC is an emerging leader specializing in the research, manufacture and marketing of clinically proven products in life sciences, beauty and personal care products. InnovaDerma has presence in Europe, US, Australasia, Asia and Africa.

action@proactiveinvestors.com

--Adds broker comment and share price--

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoVaDerma PLC named herein, including the promotion by the Company of InnoVaDerma PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).